Sotalol

Brand Names: Betapace, Sotalol Hydrochloride

Drug Class: Class III antiarrhythmic with beta-blocking properties

Overview

Sotalol is a class III antiarrhythmic agent with beta-blocking properties used to treat life-threatening ventricular arrhythmias and maintain normal sinus rhythm in patients with atrial fibrillation/flutter. It works by prolonging cardiac action potential duration and refractory periods while providing beta-adrenergic blockade. Due to its proarrhythmic potential, particularly torsade de pointes, it requires careful patient selection and monitoring.

Mechanism of Action

Sotalol has dual pharmacological actions: (1) Class III antiarrhythmic activity by blocking potassium channels, prolonging cardiac action potential duration and refractory periods, and (2) Class II beta-adrenergic blockade by competitively inhibiting beta-1 and beta-2 receptors, reducing heart rate and AV nodal conduction.

Indications

  • Treatment of documented life-threatening ventricular arrhythmias
  • Maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation/flutter

Common Doses

  • 80 mg
  • 120 mg
  • 160 mg
  • 240 mg

Dosage

Initiation requires hospitalization with continuous ECG monitoring. Typical starting dose is 80 mg twice daily, titrated gradually to 120-160 mg twice daily based on therapeutic response and QT interval monitoring. Dose adjustments required for renal impairment.

Black Box Warning

Black Box Warning: Proarrhythmic effects, particularly torsade de pointes

Contraindications

  • Sinus bradycardia
  • Sick sinus syndrome
  • Second and third degree AV block without functioning pacemaker
  • Congenital or acquired long QT syndromes
  • Cardiogenic shock or decompensated heart failure
  • Serum potassium <4.0 mEq/L
  • Baseline QTc >450 msec

Side Effects

  • Bradycardia
  • Fatigue
  • Dizziness
  • Dyspnea
  • Proarrhythmia (torsade de pointes)
  • Heart failure exacerbation
  • Hypotension
  • Bronchospasm
  • Hypoglycemia

Interactions

  • Other QT-prolonging drugs (antiarrhythmics, antipsychotics, antibiotics)
  • Calcium channel blockers (additive bradycardia)
  • Digoxin (increased risk of bradycardia)
  • Insulin and oral hypoglycemics (masked hypoglycemia symptoms)
  • Beta-2 agonists (antagonized bronchodilation)

Counseling Points

  • Take exactly as prescribed, usually twice daily
  • Do not stop abruptly without medical supervision
  • Report dizziness, fainting, palpitations, or shortness of breath immediately
  • Monitor pulse regularly as instructed
  • Maintain adequate potassium intake
  • Inform all healthcare providers about sotalol use
  • Avoid alcohol and other medications without consulting provider